MedTrace Logo

Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer

NCT04807166 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2024-07-03

No results posted yet for this study

Summary

It has been reported that antiangiogenic drugs combined with chemotherapy as first-line treatment, and subsequent antiangiogenic drugs as maintenance therapy for ovarian cancer can achieve better clinical benefits. Therefore, this study is expected to investigate the efficacy and safety of anlotinib combined with carboplatin/paclitaxel as first-line treatment in patients with advanced ovarian cancer.

Conditions

  • Ovarian Neoplasms
  • Fallopian Tube Neoplasms
  • Neoplasms by Site
  • Genital Neoplasms, Female
  • Neoplasms, Glandular and Epithelial
  • Neoplasms by Histologic Type
  • Carcinoma, Ovarian Epithelial
  • Ovarian Diseases
  • Genital Diseases, Female
  • Endocrine System Diseases
  • Carcinoma
  • Anlotinib
  • Angiogenesis
  • Antineoplastic Agents
  • Tyrosine Kinase Inhibitor

Interventions

DRUG

Drug: Anlotinib

Anlotinib will be administered orally,once a day (12 mg) on days 1-14 of a 21-day cycle

DRUG

Drug: Carboplatin/Paclitaxel

Paclitaxel 175 mg/m2 was given intravenously for 3 hours, D1 Carboplatin AUC 5 was given intravenously for 1 hour, D1

Sponsors & Collaborators

  • Wenjun Cheng

    lead OTHER

Principal Investigators

  • Wenjun Cheng, MD,PhD · The First Affiliated Hospital with Nanjing Medical University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-24
Primary Completion
2025-09-30
Completion
2027-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04807166 on ClinicalTrials.gov